Citius Pharmaceuticals, Inc.
CTXR · XNASCIK 1506251fmd_0EK6JCBWD1RNF4W6XK4CG04TJWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2009 to Jun 30, 2026, 64 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Net interest income | 0 | – | – | – | – | – | – | – | – | – |
| Cost of revenue | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Gross profit | – | 0 | 0 | – | – | – | – | – | – | – |
| Research and development | 3 | 3 | 7 | 0 | 9 | 12 | 18 | 15 | 12 | 9 |
| Total operating expenses | 7 | 10 | 14 | 16 | 18 | 24 | 33 | 37 | 42 | 39 |
| Operating income | (7) | (10) | (14) | (16) | (18) | (24) | (33) | (37) | (42) | (39) |
| Interest expense | 0 | 1 | 0 | 0 | 0 | 0 | – | – | – | 0 |
| Interest and investment income | 0 | – | – | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Other non-operating income (expense) | (1) | (0) | 1 | 0 | 0 | 0 | 0 | 5 | 3 | (0) |
| Income before taxes | (8) | 10 | 13 | (16) | (18) | (23) | (33) | (32) | (39) | (39) |
| Income tax expense | – | – | – | – | 0 | 0 | 1 | 1 | 1 | 1 |
| Net income from continuing operations | – | – | – | – | (18) | (23) | (34) | (33) | (39) | (40) |
| Net income | (8) | (10) | (13) | (16) | (18) | (23) | (34) | (33) | (39) | (40) |
| Net income to common shareholders | – | – | – | – | (18) | (25) | (34) | (34) | (40) | (37) |